Recently, Acepodia announced a strategic clinical collaboration with Pfizer Ignite, a subsidiary of Pfizer.Jointly support the development of its investigational therapies in the field of autoimmune diseases.Pfizer Ignite leverages Pfizer's extensive resources, scale, and expertise, as well as its successful experience in breakthrough drug development, to help biotechnology companies accelerate the innovation process from preclinical R&D through the entire development lifecycle.Under this agreement, Pfizer Ignite will provide Acepodia with strategic guidance and resource support to help develop potential "first-in-class" cell therapies for cancer and autoimmune diseases.
Acepodia’s Antibody Cell Conjugate (ACC) platform utilizes bioorthogonal chemistry, building on the groundbreaking work of 2022 Nobel laureate Dr. Carolyn Bertozzi in applying click chemistry to living systems, to create an off-the-shelf CAR-T cell therapy that does not require genetic engineering.This therapy is more suitable for scalable production and avoids common side effects of CAR-T cell therapy, such as cytokine release syndrome and neurotoxicity.Acepodia's first clinical-stage candidate drug, ACE1831, is an off-the-shelf γδ2 T cell therapy targeting CD20.It is currently in Phase 1 clinical trials in humans for patients with non-Hodgkin lymphoma and has demonstrated potent and durable efficacy after a single treatment at the lowest dose.
▲Acepodia's R&D Pipeline (Source: Acepodia's Official Website)
Through collaboration with Pfizer Ignite, Acepodia will benefit from Pfizer's resources, deep expertise, and R&D capabilities, covering multiple stages from clinical trial design to regulatory strategies, optimizing the development process of innovative drugs.[1]https://www.prnewswire.com
In order to allow everyone to learn and communicate with each other better,"WeChat Official Account 'Cell Gene Therapy' Team"A WeChat group for cell therapy and gene therapy has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。
Article Recommendation(Click the article title below to open the original text)：
Shanghai Announces the Establishment of a Billion-Dollar "Patient Capital" for Future Industries: Which Sectors Will Benefit?
China's First "Development Guidelines for (Cellular) Immunotherapy Products Based on mRNA-LNP Technology" Group Standard Officially Released
Acepodia's World-First Non-Gene-Edited Universal CAR-DNT Cell Therapy Approved for IND
MediCI R&D Center Officially Begins Operation
Former President of Innovent Biologics, Liu Yongjun, Takes New Position at CSPC Pharmaceutical Group
A Cell and Gene Therapy Industry Project in China Officially Breaks Ground, with a Total Investment of 7.7 Billion Yuan and a Construction Area Exceeding 200,000 Square Meters
China's National Health Commission Releases 2024 Project Application Guidelines for Six Key Special Projects, Including "Stem Cell Research and Organ Repair"
A CRO Company in China Listed on the STAR Market
NPC Deputy Suggests Including Gene-Targeted Therapy in Medical Insurance, National Health Commission Responds
Total construction area exceeds 140,000 square meters, Fosun Pharma's industrial base project officially launched
World's First, Impressive Data! Ribo Biotech Announces Phase I Clinical Data of RBD4059 for the First Time
Acepodia Launches Two Clinical Trials for Exosome Therapies Simultaneously
This company obtained the first Stem Cell Drug Manufacturing License in China.
Effective September 1! Shanghai Releases CAR-T Cell Therapy Drug Supervision Regulations
Cell Therapy Company Xueji Bio Completes New Round of Financing
Another Cell and Gene Therapy Product Approved for Marketing in China
Gene-editing company founded by two students of Zhang Feng to cease operations, received over $200 million in funding last year
World's First mRNA Lung Cancer Vaccine Clinical Trial Launched
China's First iNKT Cell Therapy Product to Enter Pivotal Clinical Stage Completes DLT Observation for Phase I, First Dose Group with Excellent Safety Data
γ-δ T Cell Therapy: 100% of Patients Achieved Complete Tumor Disappearance and Maintained for 1 Year
A platform for the clinical transformation of the gene and cell industry in China has been officially inaugurated to advance the clinical transformation and application of gene and cell therapies.
CD19/CD20 Dual-Target CAR-T Approved for Clinical Trials to Treat Autoimmune Diseases
CSPC Group's HPV mRNA Therapeutic Vaccine IND Application Accepted by CDE
China's First iNKT Cell Therapy Product to Enter Pivotal Clinical Stage Completes DLT Observation for Phase I, First Dose Group with Excellent Safety Data
Disclaimer: The content is sourced from WuXi AppTec, Prnewswire, and other sources. This article aims to share knowledge, all content is for reference only and does not constitute any advice.
